Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01252589 · ClinicalTrials.gov registry record

Patient Reported Outcomes in Chronic Myeloid Leukemia

A clinical trial of Chronic Myeloid Leukemia, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.

Completed
Registry status
480
Enrollment target
14
Study locations

NCT01252589 is a study of Chronic Myeloid Leukemia that has completed, run by Gruppo Italiano Malattie EMatologiche dell'Adulto. The registered enrollment target is 480 participants, above the 196-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (145% higher). The trial reports 14 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01252589, a study of Chronic Myeloid Leukemia, has completed, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.

COMPLETED
Registry status
480 participants
Enrollment target
14
Study locations

Study Summary

Although the impact of disease and treatment related burden on health-related quality of life (HRQOL) in patients with solid tumours has been well studied, with several clinical trials that included HRQOL as an endpoint, the general understanding in patients with Chronic Myeloid Leukaemia (CML) is lacking in comparison. The literature shows that patients' perspective is unique and should always be measured with methodologically sound instruments that are devised for this purpose. The main scope of this project is develop to an international validated questionnaire for the purpose of HRQOL assessment; such a tool will then be used to provide important data, from the patients' perspective, to make more informed treatment decisions.

Conditions Studied

Chronic Myeloid Leukemia

Interventions

  • OTHER HRQOL questionnaire

Study Locations (14)

Other

  • Innsbruck University Hospital - Innsbruck
  • University of Ghent - Ghent
  • Centre Hospitalier Universitaire of Poitiers - Poitiers
  • University of Heidelberg - Heidelberg
  • University of Athens - Athens
  • University of Baghdad - Baghdad
  • Policlinico S. Orsola - Malpighi, Università di Bologna - Bologna
  • Ematologia Ospedale "Binaghi", Cagliari - Cagliari
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori- IRST - Meldola
  • Ospedale S.Maria delle Croci - Ravenna
  • Ematologia - Sapienza Università di Roma - Roma
  • Tilburg University - Tilburg
  • National Taiwan University - Taipei

Massachusetts

  • Dana-Farber Cancer Institute Harvard University - Boston

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2010-11
Est. Completion 2013-09

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01252589

The ClinicalTrials.gov registry entry for NCT01252589 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (145% higher). The listed sponsor is Gruppo Italiano Malattie EMatologiche dell'Adulto, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which HRQOL questionnaire is the first listed.

NCT01252589 reports 14 study locations spanning 2 distinct geographic areas - top geographies include Other, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01252589 about?

NCT01252589 is a clinical study titled "Patient Reported Outcomes in Chronic Myeloid Leukemia". Although the impact of disease and treatment related burden on health-related quality of life (HRQOL) in patients with solid tumours has been well studied, with several clinical trials that included HRQOL as an endpoint, the general understanding in patients with Chronic Myeloid Leukaemia (CML) is l...

What is the current status of trial NCT01252589?

This trial is currently completed. The enrollment target is 480 participants. The study started on 2010-11. Estimated completion is 2013-09.

What conditions does trial NCT01252589 study?

This clinical trial studies the following conditions: Chronic Myeloid Leukemia.

What interventions are being tested in trial NCT01252589?

The interventions under investigation include: HRQOL questionnaire (OTHER).

Who is sponsoring clinical trial NCT01252589?

This trial is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01252589 being conducted?

This trial has 14 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Myeloid Leukemia

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.